These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 19616835)

  • 1. Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy.
    Tsivian M; Sun L; Mouraviev V; Madden JF; Mayes JM; Moul JW; Polascik TJ
    Urology; 2009 Nov; 74(5):1090-3. PubMed ID: 19616835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ribosome-binding protein-1 (RRBP1) expression in prostate carcinomas and its relationship with clinicopathological prognostic factors.
    Kuzuluk DG; Secinti IE; Erturk T; Hakverdi S; Gorur S; Ozatlan D
    Scott Med J; 2024 May; ():369330241245730. PubMed ID: 38711311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional variants of the chitinase 3-like 1 gene are associated with clinicopathologic outcomes and progression of prostate cancer.
    Wen YC; Lin CY; Ho KH; Lin YW; Hsiao CH; Wang SS; Chang LC; Yang SF; Chien MH
    J Cell Mol Med; 2023 Dec; 27(24):4202-4214. PubMed ID: 37902124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and validation of N6-methyladenosine long non-coding RNAs signature of prognostic value for early biochemical recurrence of prostate cancer.
    Liu J; Zhang W; Wang J; Lv Z; Xia H; Zhang Z; Zhang Y; Wang J
    J Cancer Res Clin Oncol; 2023 May; 149(5):1969-1983. PubMed ID: 35731271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical recurrence related metabolic novel signature associates with immunity and ADT treatment responses in prostate cancer.
    Wang X; Lv Z; Xia H; Guo X; Wang J; Wang J; Liu M
    Cancer Med; 2023 Jan; 12(1):862-878. PubMed ID: 35681277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Evaluation of FOXO1 as a Tumor Suppressor in Prostate Cancer.
    Yang N; Wu J; Zhang T; Yang F; Shao J; He C; Qin L
    Comput Math Methods Med; 2021; 2021():8773423. PubMed ID: 34552661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A qualitative transcriptional signature for predicting the biochemical recurrence risk of prostate cancer patients after radical prostatectomy.
    Li X; Huang H; Zhang J; Jiang F; Guo Y; Shi Y; Guo Z; Ao L
    Prostate; 2020 Apr; 80(5):376-387. PubMed ID: 31961962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Factors and Oncologic Outcome of Downgrade to Pathologic Gleason Score 6⁻7 after Radical Prostatectomy in Patients with Biopsy Gleason Score 8⁻10.
    Chung DY; Lee JS; Goh HJ; Koh DH; Kim MS; Jang WS; Choi YD
    J Clin Med; 2019 Mar; 8(4):. PubMed ID: 30935044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current status of renal cell carcinoma and prostate carcinoma grading.
    Delahunt B; Egevad L; Yaxley J; Samaratunga H
    Int Braz J Urol; 2018; 44(6):1057-1062. PubMed ID: 30516924
    [No Abstract]   [Full Text] [Related]  

  • 10. Reduced Connexin 43 expression is associated with tumor malignant behaviors and biochemical recurrence-free survival of prostate cancer.
    Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
    Oncotarget; 2016 Oct; 7(41):67476-67484. PubMed ID: 27623212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Grading of prostatic adenocarcinoma: current state and prognostic implications.
    Gordetsky J; Epstein J
    Diagn Pathol; 2016 Mar; 11():25. PubMed ID: 26956509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refining treatment for the men who need it: lessons from the PIVOT trial.
    Abern MR; Tsivian M; Polascik TJ
    Transl Androl Urol; 2013 Jun; 2(2):82-4. PubMed ID: 26816728
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy.
    Faraj SF; Bezerra SM; Yousefi K; Fedor H; Glavaris S; Han M; Partin AW; Humphreys E; Tosoian J; Johnson MH; Davicioni E; Trock BJ; Schaeffer EM; Ross AE; Netto GJ
    PLoS One; 2016; 11(1):e0146189. PubMed ID: 26731672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of molecular biomarkers expression with biochemical recurrence in prostate cancer through tissue microarray immunostaining.
    Ma D; Zhou Z; Yang B; He Q; Zhang Q; Zhang XH
    Oncol Lett; 2015 Oct; 10(4):2185-2191. PubMed ID: 26622816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gleason grading challenges in the diagnosis of prostate adenocarcinoma: experience of a single institution.
    Chen SD; Fava JL; Amin A
    Virchows Arch; 2016 Feb; 468(2):213-8. PubMed ID: 26563400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of the 2005 International Society of Urological Pathology (ISUP) modified Gleason grading system as a predictor of biochemical recurrence after radical prostatectomy.
    Billis A; Quintal MM; Meirelles L; Freitas LL; Costa LB; Bonfitto JF; Diniz BL; Poletto PH; Magna LA; Ferreira U
    Int Urol Nephrol; 2014 May; 46(5):935-40. PubMed ID: 24096373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system.
    Pierorazio PM; Walsh PC; Partin AW; Epstein JI
    BJU Int; 2013 May; 111(5):753-60. PubMed ID: 23464824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer.
    Li D; Chiu H; Gupta V; Chan DW
    Clin Chim Acta; 2012 Oct; 413(19-20):1506-11. PubMed ID: 22722017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?
    Ross HM; Kryvenko ON; Cowan JE; Simko JP; Wheeler TM; Epstein JI
    Am J Surg Pathol; 2012 Sep; 36(9):1346-52. PubMed ID: 22531173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The additional value of TGFβ1 and IL-7 to predict the course of prostate cancer progression.
    Schroten C; Dits NF; Steyerberg EW; Kranse R; van Leenders AG; Bangma CH; Kraaij R
    Cancer Immunol Immunother; 2012 Jun; 61(6):905-10. PubMed ID: 22113713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.